Corgenix, Rebio Gen extend technology agreement for hyaluronic acid test

By Lisa Kerner

Erie, Pa., Feb. 2 - Corgenix Medical Corp. has executed an extension to the technology license agreement with Rebio Gen Inc., a subsidiary of Fujirebio Inc., Tokyo, according to a company news release.

The license agreement provides Corgenix with the U.S. and worldwide rights to intellectual property to manufacture and market a microplate format ELISA test that measures hyaluronic acid. The rights to not extend to Japan.

The extension licenses the technology to Corgenix through the expiration of the patents.

Corgenix said clinical studies have shown a correlation between hyaluronic acid levels in the blood of patients with chronic liver disease and the degree of tissue damage to the liver (fibrosis or scarring).

The assessment of liver damage is performed primarily by repeated histological examinations of a liver biopsy. The hyaluronic acid test manufactured by Corgenix is a less costly serologic marker for liver damage.

Denver-based Corgenix develops and manufactures specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.